Recent BayBio Life Science Series VC Spotlight Panel Discussion: Follow-on Biologics, Biosimilars, and Biobetters


BayBio Life Science Series VC Spotlight hosted an interesting panel discussion entitled Follow-on Biologics, Biosimilars, Biobetters on May 5, 2011 in South San Francisco. Rob Jacoby of Deloitte Consulting LLP moderated the event, which included panelists Sarah Bodary of SV Life Sciences; Ted Buckley of Bloomberg Government; Robert Kastelein of Merck & Co., Inc.; Andrew McMillan of 5AM Ventures; and H. Daniel Perez of Bay City Capital.

The panelists’ comments reflected guardedly positive views on prospects for development of biosimilar products in the US. McMillan remarked that 5AM Ventures has invested in at least one biosimilar project and anticipates additional investments as attractive opportunities arise. Bodary envisioned greater biosimilar development success for small, nimble biotech companies than large ones. Buckley noted that there has been much faster market adoption of biosimilar products in Europe than was predicted. For example, Germany has already seen almost 60% market adoption of biosimilar products, although many analysts predicted only 10-30% within the first two years after approval. Several panelists noted that the market adoption rate is highly dependant on insurance reimbursements, tiered pricing regimes, and the medical payor situation, which are currently in flux in the US. Buckley also observed that development of biosimilars will depend on the level of certainty regarding regulatory requirements for drug approval, and noted that Dr. Rachel Behrman, Associate Director of Medical Policy at CDER, recently predicted in an interview on BioCentury This Week that FDA’s requirements for establishing biosimilarity will be determined on a case-by-case basis, and that the FDA will not provide advice regarding necessary any animal and human testing until after it has reviewed the biosimilar applicant’s analytical data for the biosimilar in comparison to the reference biologic.

Please see full article below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Dechert LLP | Attorney Advertising

Written by:


Dechert LLP on:

JD Supra Readers' Choice 2016 Awards
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.